News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
838,593 Results
Type
Article (86094)
Company Profile (649)
Press Release (751850)
Multimedia
Podcasts (128)
Webinars (14)
Section
Business (232215)
Career Advice (4124)
Deals (39708)
Drug Delivery (126)
Drug Development (90793)
Employer Resources (198)
FDA (17998)
Job Trends (17322)
News (395552)
Policy (39672)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (6)
2025 BioForest Digital (7)
2025 Lone Star Bio Digital (8)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2992)
Academic (1)
Accelerated approval (6)
Adcomms (25)
Allergies (78)
Alliances (56656)
ALS (79)
Alzheimer's disease (1467)
Antibody-drug conjugate (ADC) (141)
Approvals (17984)
Artificial intelligence (222)
Autoimmune disease (27)
Automation (12)
Bankruptcy (402)
Best Places to Work (12511)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (447)
Bladder cancer (67)
Brain cancer (25)
Breast cancer (226)
Cancer (1962)
Cardiovascular disease (140)
Career advice (3530)
Career pathing (34)
CAR-T (156)
Cell therapy (435)
Cervical cancer (17)
Clinical research (72786)
Collaboration (771)
Compensation (440)
Complete response letters (28)
COVID-19 (2828)
CRISPR (42)
C-suite (216)
Cystic fibrosis (99)
Data (1795)
Decentralized trials (2)
Denatured (45)
Depression (37)
Diabetes (184)
Diagnostics (6751)
Digital health (9)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (118)
Drug pricing (94)
Drug shortages (17)
Duchenne muscular dystrophy (81)
Earnings (95281)
Editorial (36)
Employer branding (25)
Employer resources (167)
Events (128351)
Executive appointments (606)
FDA (18925)
Featured Employer (63)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (646)
Gene editing (97)
Generative AI (22)
Gene therapy (310)
GLP-1 (735)
Government (5107)
Grass and pollen (4)
Guidances (35)
Healthcare (20743)
Huntington's disease (25)
IgA nephropathy (26)
Immunology and inflammation (127)
Indications (24)
Infectious disease (2943)
Inflammatory bowel disease (148)
Inflation Reduction Act (11)
Influenza (43)
Intellectual property (84)
Interviews (812)
IPO (17688)
IRA (38)
Job creations (5185)
Job search strategy (2861)
Kidney cancer (11)
Labor market (41)
Layoffs (538)
Leadership (20)
Legal (10057)
Liver cancer (71)
Lung cancer (285)
Lymphoma (132)
Machine learning (5)
Management (65)
Manufacturing (284)
MASH (68)
Medical device (14298)
Medtech (14303)
Mergers & acquisitions (22273)
Metabolic disorders (590)
Multiple sclerosis (75)
NASH (22)
Neurodegenerative disease (97)
Neuropsychiatric disorders (23)
Neuroscience (1951)
NextGen: Class of 2025 (7666)
Non-profit (5055)
Northern California (2286)
Now hiring (40)
Obesity (317)
Opinion (270)
Ovarian cancer (68)
Pain (65)
Pancreatic cancer (61)
Parkinson's disease (131)
Partnered (19)
Patents (193)
Patient recruitment (91)
Peanut (48)
People (64868)
Pharmaceutical (131)
Pharmacy benefit managers (13)
Phase I (22486)
Phase II (31646)
Phase III (23793)
Pipeline (996)
Policy (139)
Postmarket research (3542)
Preclinical (10105)
Press Release (72)
Prostate cancer (83)
Psychedelics (34)
Radiopharmaceuticals (250)
Rare diseases (354)
Real estate (7383)
Recruiting (75)
Regulatory (26407)
Reports (55)
Research institute (2646)
Resumes & cover letters (649)
Rett syndrome (1)
RNA editing (4)
RSV (34)
Schizophrenia (68)
Series A (125)
Series B (72)
Service/supplier (25)
Sickle cell disease (46)
Southern California (1949)
Special edition (18)
Spinal muscular atrophy (164)
Sponsored (34)
Startups (4285)
State (2)
Stomach cancer (11)
Supply chain (50)
Tariffs (32)
The Weekly (81)
United States (19591)
Vaccines (727)
Venture capitalists (41)
Weight loss (228)
Women's health (37)
Worklife (19)
Date
Last 7 days (528)
Last 30 days (1878)
Last 365 days (28975)
2025 (8240)
2024 (34031)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1265)
Alabama (53)
Alaska (6)
Arizona (244)
Arkansas (8)
Asia (49826)
Australia (8792)
California (5207)
Canada (1555)
China (482)
Colorado (165)
Connecticut (208)
Delaware (125)
Europe (114005)
Florida (648)
Georgia (145)
Hawaii (1)
Idaho (64)
Illinois (439)
India (25)
Indiana (270)
Iowa (10)
Japan (133)
Kansas (109)
Kentucky (16)
Louisiana (8)
Maine (58)
Maryland (829)
Massachusetts (4103)
Michigan (182)
Minnesota (308)
Mississippi (1)
Missouri (53)
Montana (24)
Nebraska (26)
Nevada (52)
New Hampshire (50)
New Jersey (1491)
New Mexico (27)
New York (1470)
North Carolina (994)
North Dakota (7)
Northern California (2286)
Ohio (162)
Oklahoma (13)
Oregon (45)
Pennsylvania (1103)
Puerto Rico (11)
Rhode Island (23)
South America (1648)
South Carolina (4)
South Dakota (1)
Southern California (1949)
Tennessee (30)
Texas (689)
Utah (115)
Virginia (101)
Washington D.C. (39)
Washington State (510)
West Virginia (1)
Wisconsin (38)
838,593 Results for "emerald bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients
February 24, 2025
·
4 min read
Press Releases
Okogen Announces Regulatory Submission to CDSCO for EMERALD STUDY and Appointment of New Chief Medical Officer
April 2, 2025
·
2 min read
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline
Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.
March 25, 2025
·
2 min read
·
Dan Samorodnitsky
Layoffs
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway
Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.
January 13, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Granite Bio Debuts With $100 Million of Capital
April 24, 2025
·
6 min read
Drug Development
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis.
October 9, 2023
·
1 min read
Press Releases
Senti Bio Participates in a Virtual Investor KOL Connect Segment
April 21, 2025
·
5 min read
Press Releases
Adicet Bio Appoints Michael Grissinger to the Board of Directors
April 17, 2025
·
4 min read
Press Releases
FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors
April 22, 2025
·
5 min read
1 of 83,860
Next
